These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12634732)

  • 41. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Split chimerism may be enough to cure Evans syndrome.
    Caselli D; Farruggia P; Trizzino A; Cannella S; Santoro A; Locatelli F; Aricò M
    Bone Marrow Transplant; 2006 Aug; 38(4):311. PubMed ID: 16785863
    [No Abstract]   [Full Text] [Related]  

  • 43. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Severe acute graft-versus-host disease after T-cell depleted allogeneic stem cell graft from a second donor caused by persisting T-cells from the first donor.
    Wiesmann A; Bader P; Bamberg M; Faul C; Kanz L; Einsele H
    Bone Marrow Transplant; 2003 Sep; 32(5):511-3. PubMed ID: 12942098
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
    Michallet AS; Nicolini F; Michallet M
    Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
    Ma SY; Au WY; Lie AK; Ng IO; Leung AY; Tse EW; Liang RH; Lau GK; Kwong YL
    Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7.
    Skinner R; Velangi M; Bown N
    Pediatr Blood Cancer; 2008 Mar; 50(3):670-2. PubMed ID: 17253642
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
    Jillella AP; Shafer D; Klumpp TR; Emmons RV; Mangan KF
    Am J Hematol; 2007 Jun; 82(6):419-26. PubMed ID: 17211845
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Haematopoetic stem cell transplantation for refractory autoimmune cytopenia.
    Passweg JR; Rabusin M; Musso M; Beguin Y; Cesaro S; Ehninger G; Espigado I; Iriondo A; Jost L; Koza V; Lenhoff S; Lisukov I; Locatelli F; Marmont A; Philippe P; Pilatrino C; Quartier P; Stary J; Veys P; Vormoor J; Wahlin A; Zintl F; Bocelli-Tyndall C; Tyndall A; Gratwohl A;
    Br J Haematol; 2004 Jun; 125(6):749-55. PubMed ID: 15180864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect.
    Van Wijmeersch B; Sprangers B; Rutgeerts O; Lenaerts C; Landuyt W; Waer M; Billiau AD; Dubois B
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):627-37. PubMed ID: 17531772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.
    Levenga H; Woestenenk R; Schattenberg AV; Maas F; Jansen JH; Raymakers R; De Mulder PH; van de Wiel-van Kemenade E; Schaap N; de Witte T; Dolstra H
    Bone Marrow Transplant; 2007 Sep; 40(6):585-92. PubMed ID: 17637687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Allogeneic hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis type 1: a case report].
    Ou RM; Wang L; Zheng LL; Yao MD; Jiang WT; Zhou CH
    Zhongguo Dang Dai Er Ke Za Zhi; 2006 Jun; 8(3):181-3. PubMed ID: 16787585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.
    Raj K; Narayanan S; Augustson B; Ho A; Mehta P; Duncan N; Tauro S; Mahendra P; Craddock C; Mufti G
    Bone Marrow Transplant; 2005 Feb; 35(3):299-301. PubMed ID: 15568036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
    Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience.
    Hallböök H; Hägglund H; Stockelberg D; Nilsson PG; Karlsson K; Björkholm M; Linderholm M; Wahlin A; Linder O; Smedmyr B;
    Bone Marrow Transplant; 2005 Jun; 35(12):1141-8. PubMed ID: 15834433
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplant.
    Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
    Bone Marrow Transplant; 2004 Jan; 33(2):231-6. PubMed ID: 14647258
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
    Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population.
    Levine JE; Barrett AJ; Zhang MJ; Arora M; Pulsipher MA; Bunin N; Fort J; Loberiza F; Porter D; Giralt S; Drobyski W; Wang D; Pavletic S; Ringden O; Horowitz MM; Collins R
    Bone Marrow Transplant; 2008 Aug; 42(3):201-5. PubMed ID: 18490913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.